We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The European Medicines Agency (EMA) has expanded its recommendations for compassionate use of Gilead Sciences’ remdesivir for patients with severe COVID-19. Read More
The National Institutes of Health is sponsoring a clinical trial of Gilead Sciences’ antiviral remdesivir combined with Eli Lilly’s anti-inflammatory Olumiant (baricitinib) for treatment of COVID-19 infections. Read More
HHS has not yet used its new authority under the 21st Century Cures Act to recruit more senior biomedical scientists for the FDA and other agencies, the Government Accountability Office said in a new report released Friday. Read More
Maryland Gov. Larry Hogan last week vetoed legislation that would have funded the state’s Prescription Drug Affordability Board, an independent body established last year to evaluate costly drugs and set price caps. Read More
Following widespread criticism of the federal government’s handling of COVID-19 treatment remdesivir, HHS released details on Saturday of its distribution plan of the drug, and said states will make the final call on which hospitals get the drug. Read More